- Paolo Bruzzi, National Cancer Research Institute
- Carlos Caldas, Cambridge Research Institute
- Ian Cree, Warwick Medical School, Coventry
- Shoukat Dedhar, British Columbia Cancer Agency
- John A Hartley, University College London
- Manami Inoue, University of Tokyo
- Mark McKeage, University of Auckland
- Christophe Nicot, Kansas University Medical Center
- Stephen P Povoski, The Ohio State University
- Dirk Vordermark, Martin Luther University Halle-Wittenberg
- Dafne Solera, BioMed Central
Whole-exome sequencing of primary, metastatic and recurrent ovarian carcinoma from a single BRCA1-positive patient is a powerful method to detect subsequent somatic mutations and can provide information about the molecular evolution of BRCA1-driven ovarian cancer.
The protein tyrosine phosphatase PRL-3 (Phosphatase of Regenerating Liver-3) is highly expressed in human ovarian cancer patient samples and may promote cancer cell migration, invasion and metastasis via inhibition of c-fos transcriptional regulation of integrin alpha2 signaling.
Recurrence-free female young adult survivors of non-gynecologic malignancies are less likely than controls to give birth after diagnosis, and the overall modest effect is influenced by pre-diagnosis childbirth and malignancy type.
- View more articles
News from the web
- 19 June 2013
- Polyp growth identifies colorectal cancer
- 17 June 2013
- Early motherhood reduces kidney cancer risk
BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.
It is journal policy to publish work deemed by peer reviewers to be a coherent and sound addition to scientific knowledge and to put less emphasis on interest levels, provided that the research constitutes a useful contribution to the field.
Join the Editorial Board!
Are you interested in becoming an Editorial Board member for BMC Cancer and helping to maintain the editorial standards and ethos of this growing journal? To volunteer as an Associate Editor, please simply contact us at firstname.lastname@example.org, enclosing a summary of your research interests and relevant expertise. We look forward to hearing from you.
Christudas Morais, David W Johnson, David A Vesey, and Glenda C Gobe1BMC Cancer 2013, 13:14 (10 January 2013)
Section Editor's profile
Mark McKeage is a medical oncologist and associate professor in the department of pharmacology and clinical pharmacology and co-director of the Auckland Cancer Society Research Centre at the university of Auckland, New Zealand. His current research focuses on how membrane transporters determine response and handling of platinum-based anticancer drugs. In addition, he leads a programme of phase I oncology trials at his centre.
"BMC Cancer is the leading Open Access international journal in the field of oncology. By publishing over 500 articles per year, BMC Cancer offers rapid dissemination of the most recent information of interest to the broad oncology science community."
Prof McKeage is the Section Editor of the Clinical oncology- medical oncology and pharmacology section of BMC Cancer.